arrow
H

He Wang

chinese academy of sciences
H指数:7
被引数:193

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evolutionary convergence and divergence of hippocampal cytoarchitecture between rodents and primates revealed by single-cell spatial transcriptomics

通过单细胞空间转录组学揭示啮齿类和灵长类海马区细胞构筑的进化趋异与趋同

2026-03-010
PRE
Investigating the Role of Glycolysis in Xuefu Zhuyu Capsule-Promoted Angiogenesis in Endothelial Cells: A Study Based on Network Pharmacology, Molecular Docking, and In Vitro Validation

探究Xuefu Zhuyu Capsule促进内皮细胞血管生成的糖酵解作用:一项基于网络药理学、分子对接和体外验证的研究

2025-12-180
OAAI
Hyperactivity of subicular parvalbumin interneurons drives early amyloid pathology and cognitive deficits in Alzheimer’s disease

海马伞室旁蛋白 interneuron 的过度活跃驱动阿尔茨海默病早期的淀粉样蛋白病理和认知缺陷。

2025-09-060
OAAI
Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: study protocol of a multicenter single-arm phase II trial

评估迪斯他姆单抗维多汀联合替雷利珠单抗和盆腔淋巴结清扫在肌层浸润性膀胱癌患者中保膀胱方案的有效性与安全性:一项多中心单臂II期试验研究方案

2025-05-130
OA
Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial (vol 4, pg 135, 2024)

奥沙利铂脂质体与奥沙利铂联合卡铂在卵巢癌一线化疗中的疗效与安全性:一项多中心、开放标签、非劣效性、随机对照试验(卷4,页135,2024)

2025-02-010
OAAI
Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial

紫杉醇脂质体与紫杉醇联合卡铂一线化疗治疗卵巢癌的疗效和安全性比较: 一项多中心、开放、非劣效性、随机对照试验

2024-06-011
OAAI
Discovery of a novel lipid metabolism-related gene signature to predict outcomes and the tumor immune microenvironment in gastric cancer by integrated analysis of single-cell and bulk RNA sequencing

通过对单细胞和批量RNA测序的集成分析发现一种新的脂质代谢相关基因签名,以预测胃癌的预后和肿瘤免疫微环境

2023-12-023
OAAI